Patrick Mismetti

Patrick Mismetti

Auto-generated profile, based on publicly available information

Patrick Mismetti

F-CRIN INNOVTE Network, Saint-Étienne, France (I.M., F.C., P.M., S.L.).

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Hamostaseologie
Verified
Journal Article
Open access
PDF file
FCFabrice Cognasse
Fabrice Cognasse
KHKathryn Hally
Kathryn Hally
SFSebastien Fauteux-Daniel
Sebastien Fauteux-Daniel
MEMarie-Ange Eyraud
Marie-Ange Eyraud
CACharles-Antoine Arthaud
Charles-Antoine Arthaud
PLPeter Larsen
Peter Larsen
Aside from their canonical role in hemostasis, it is increasingly recognized that platelets have inflammatory functions and can regulate both adaptive and innate immune responses. The main topic this review aims to cover is the proinflammatory effects and side effects of platelet transfusion. Platelets prepared for transfusion are subject to stress injury upon collection, preparation, and storage. With these types of stress, they undergo morphologic, metabolic, and functional modulations which are likely to induce platelet activation and the release of biological response modifiers (BRMs). As a consequence, platelet concentrates (PCs) accumulate BRMs during processing and storage, and these BRMs are ultimately transfused alongside platelets. It has been shown that BRMs present in PCs can induce immune responses and posttransfusion reactions in the transfusion recipient. Several recent reports within the transfusion literature have investigated the concept of platelets as immune cells. Nevertheless, current and future investigations will face the challenge of encompassing the immunological role of platelets in the scope of transfusion.

1 January 1997 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
BTBernard Tardy
Bernard Tardy
BTBrigitte Tardy
Brigitte Tardy
SLSilvy Laporte‐Simitsidis
Silvy Laporte‐Simitsidis
PMPatrick Mismetti
Patrick Mismetti
HDHervé Decousus
Hervé Decousus
JBJean C. Bertrand
Jean C. Bertrand
A double‐blind randomized trial was conducted to research a hypercoagulable state rebound after abrupt versus gradual withdrawal of acenocoumarol. 20 patients were included: 10 in the abrupt withdrawal group (AW) and 10 in the gradual withdrawal group (GW). Between days 1 and 15, F1+2 was higher in group AW (P<0.002). A sig‐nificant increase of D‐dimer with time was found (P<0.001) without difference between the two groups. tPA and PAI‐1 levels remained stable throughout without difference between the two groups. No rebound phenomenon was observed. Four thrombotic recurrences were observed: group AW: 1, group GW: 3 (P=0.29). There is neither clinical nor biological support for a gradual anticoagulation withdrawal.

1 November 2019 in Respiratory Medicine and Research
Verified
Journal Article
Closed access
JCJ. Catella-Chatron
J. Catella-Chatron
AMA. Merah
A. Merah
EME. De Magalhaes
E. De Magalhaes
NMN. Moulin
N. Moulin
SAS. Accassat
S. Accassat
LBLaurent Bertoletti
Laurent Bertoletti

2 January 2022 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
LLLudovic Lafaie
Ludovic Lafaie
TCThomas Célarier
Thomas Célarier
MMManuel Monreal
Manuel Monreal
PMPatrick Mismetti
Patrick Mismetti
XDXavier Delavenne
Xavier Delavenne
LBLaurent Bertoletti
Laurent Bertoletti
Management of venous thromboembolic events (VTE) has been completely changed after the introduction of direct oral anticoagulants (DOAC). VTE is common in the geriatric population, but the manageme...

1 June 2008 in Pathologie Biologie
Verified
Journal Article
Closed access
PMP. Mismetti
P. Mismetti
KRK. Rivron-Guillot
K. Rivron-Guillot
NMN. Moulin
N. Moulin

20 November 2009 in Blood
Verified
Journal Article
Open access
SSSam Schulman
Sam Schulman
HEHenry Eriksson
Henry Eriksson
SGSamuel Z. Goldhaber
Samuel Z. Goldhaber
AKAjay K Kakkar
Ajay K Kakkar
CKClive Kearon
Clive Kearon
JSJanet Schnee
Janet Schnee
Abstract 1 Background. The direct oral thrombin inhibitor, dabigatran etexilate, has a predictable anticoagulant effect and may be an alternative to warfarin in patients with acute venous thromboembolism (VTE). Methods. In a randomized, double-blind, trial of 2539 patients with acute VTE, treated with low molecular weight or unfractionated heparin for 5 to 11 days, we compared oral dabigatran etexilate, 150 mg twice daily in a fixed-dose, with warfarin dose-adjusted to an International Normalized Ratio of 2.0 and 3.0, each given for 6 months. The primary outcome was symptomatic, objectively confirmed recurrent VTE or VTE-related death up to 6 months of treatment. Safety endpoints included bleeding events, acute coronary syndrome, liver function tests, vital signs and adverse events. Results. Of 1274 patients randomized to dabigatran etexilate, at 6 months 30 (2.4%) had recurrent VTE compared with 27 (2.2%) of 1265 patients randomized to warfarin; risk difference 0.4% [95 percent confidence interval, −0.8 to 1.5]; p<0.0001 for prespecified non-inferiority margin. During the planned study participation, through the end of the follow-up period, there were 34 vs. 32 patients who had recurrent VTE in the dabigatran etexilate vs. warfarin treated groups, respectively (hazard ratio 1.05 [95% confidence interval, 0.065 to 1.70]). Major bleeding occurred in 20 patients treated with dabigatran etexilate and 24 patients treated with warfarin (hazard ratio 0.82; 95 percent confidence interval, 0.45 to 1.48) and any bleeding occurred in 207 versus 280 patients, respectively (hazard ratio 0.71, 95 percent confidence interval, 0.59 to 0.85). Death, acute coronary syndromes, and liver function test abnormalities were infrequent and similar in the two groups. Conclusion: Fixed-dose dabigatran etexilate is as effective and safe as warfarin in the treatment of acute VTE.